In 2013 there were ~200 million clinical cases of malaria, causing ~600,000 deaths. All antimalarial drugs are now associated with malaria parasite resistance. Thus, new therapies are urgently needed, including new drugs to prevent this disease. We have made the exciting discovery that an existing antimalarial drug can kill malaria parasites in a unique, previously unknown, manner. Here, we will investigate how this occurs and develop new drug candidates for malaria prevention.
Validation Of Formyl Peptide Receptor (FPR)2 As A Target For New Anti-cancer Drugs
Funder
National Health and Medical Research Council
Funding Amount
$588,529.00
Summary
Treatment of breast and other cancers is making incremental improvements, but premature death from this disease and its recurrence in some women after a long period of remission are not adequately treated by current drugs. New work has identified a target called FPR2 that could be used to guide the development of novel drugs. The current project seeks to validate the new drug target, before resource intensive efforts are made to find suitable drugs.
The Control And Regulatory Mechanisms Of Artemisinin Induced Dormancy In P. Falciparum
Funder
National Health and Medical Research Council
Funding Amount
$495,552.00
Summary
Malaria is a major global health problem and can only be reliably treated with artemisinin combinations in many areas due to widespread of drug resistance. However a proportion of parasites appear to be able to avoid the lethal effects of the drug by becoming “dormant” following exposure. They resume growth after the drug is wanned, a feature which is reminisent to cell cycle arrest. This study investigates the role of cell cycle machinery in dormancy following arteminsinin treatment.
Reducing The Burden Of Orthostatic Intolerance - Delineating Mechanisms And Improving Therapy
Funder
National Health and Medical Research Council
Funding Amount
$411,735.00
Summary
Orthostatic intolerance (OI) represents a heterogenous group of complex disorders which are poorly understood and lack effective treatment. They are frequently disabling and may severely impact on quality of life. In the proposed project, we will undertake a systematic investigation of _sympathetic nervous system� in OI patients and assess the clinical effect of a drug _L-DOPS� in subjects suffering from OI.
Application Of New Chemistry Approaches For Antimalarial Drug Discovery
Funder
National Health and Medical Research Council
Funding Amount
$74,263.00
Summary
Malaria kills approximately one million people annually. Currently there no vaccine and many of the available drugs are becoming less effective due the resistance of this highly adaptable parasite. My aim is to develop new chemical classes of drugs that inhibit different targets in the malaria parasite to the currently available drugs. In addition to this I aim to improve the present systems for assessing antimalarial drug effects using new chemical approaches and live parasite assays.
Molecular Dissection Of The Actin Cytoskeleton In Exocytosis Using Intravital Microscopy
Funder
National Health and Medical Research Council
Funding Amount
$1,206,869.00
Summary
The proteins actin and tropomyosin form networks in cells that are involved in all of the key processes that are hijacked when a cell becomes cancerous. We discovered that the tropomyosin is the key to the function of a network and have developed drugs that target the cancer-associated tropomyosin. We will examine how the drugs kill cancer cells using a novel method, developed by us, to visualize drug activity in real time, and validate their impact on the target filaments in living tissue.
Small Molecule Inhibitors To Reprogram The Tumour Environment And Improve Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$784,520.00
Summary
Cancer blood vessels are different to normal blood vessels; they help cancer cells to spread and stop immune cells in their tracks. We have identified drugs which help to make cancer blood vessels more normal and also bring immune cells into the cancer core. We will test these drugs in combination with immunotherapies, a new treatment option which has not reached its full potential in the clinic. Since our drug candidates are already in clinical use, we expect to fast track clinical development.
Regulation Of Human Arylamine N-acetyltransferase Transcription, Translation And Protein Stability
Funder
National Health and Medical Research Council
Funding Amount
$470,958.00
Summary
Individuals respond very differently to many drugs and other chemicals in the diet and workplace. This variation can be a significant complication in treating patients and in attempting to determine risk with exposure to toxins. Genetic differences between individuals are a common reason for this variation. However, many enzymes and other proteins in humans are controlled by environmental factors that can either increase their activity or inhibit it. In this study, we will investigate how the ac ....Individuals respond very differently to many drugs and other chemicals in the diet and workplace. This variation can be a significant complication in treating patients and in attempting to determine risk with exposure to toxins. Genetic differences between individuals are a common reason for this variation. However, many enzymes and other proteins in humans are controlled by environmental factors that can either increase their activity or inhibit it. In this study, we will investigate how the activity of an important family of enzymes (the acetyltransferases) varies between individuals as a result of environmental factors. We will look at the genes for each of the enzymes and learn about this control mechanism. We will also look careful at the structure of the proteins and determine how this may change when challenged with external stimuli. The expected outcome will be a better understanding of these important enzymes that are involved in the metabolism of many drugs, and also provide a means of determining how different individuals may respond to foreign chemicals and drugs that use these enzymes in the body for metabolism.Read moreRead less
Understanding The Side Effects Of HAART In HIV Patients
Funder
National Health and Medical Research Council
Funding Amount
$387,489.00
Summary
Combination therapy has dramatically improved the life expectancy of people living with HIV. However, the long term side effects of these medications can be significant. Not everyone treated with the same drugs suffers similar side effects. This project seeks to unravel factors that lead a given individual to experience particular side effects. Understanding why medication side effects occur will be critical in finding safer ways to treat HIV.
Expression And Regulation Of Human Genes Central To Drug Disposition In The Brain
Funder
National Health and Medical Research Council
Funding Amount
$339,375.00
Summary
The study of the regulation of human genes is inherently difficult. It is difficult or impossible to gain access to many body tissues in either healthy or sick individuals to examine coordinated gene function (or dysfunction). This is particularly true for the brain, where live human tissue is unavailable. For this reason, it is often the case that we have a much better understanding of gene function in species such as rats and mice, the most common animal environments for biomedical research. H ....The study of the regulation of human genes is inherently difficult. It is difficult or impossible to gain access to many body tissues in either healthy or sick individuals to examine coordinated gene function (or dysfunction). This is particularly true for the brain, where live human tissue is unavailable. For this reason, it is often the case that we have a much better understanding of gene function in species such as rats and mice, the most common animal environments for biomedical research. However, findings in animals often fail to meaningfully mirror what occurs in man. To progress our understanding of human genes in brain we need to develop models that more faithfully reproduce the human situation in an environment that is amenable to both manipulation and close examination, such as the novel 'humanized' mouse models described in this application. This application deals with the genes that control enzymes belonging to the human cytochrome P450 3A (CYP3A) subfamily and the drug transporter MDR1. These genes are present in several tissues including liver, gut, lung and brain. They form the main disposal pathway for foreign chemicals such as drugs, environmental pollutants and some cancer causing chemicals. In addition they are involved in the breakdown of several important internally produced substances, such as steroid hormones. We postulate that altered formation of CYP3A enzymes and MDR1 in brain can have a dramatic impact on the action of many important drugs and may affect the way the brain responds in a behavioral sense to hormones, such as sex steroids. In addition, this work will provide a new and useful information relevant to the design and development of the plethora of drugs that act on the central nervous system.Read moreRead less